187 related articles for article (PubMed ID: 15964668)
1. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography.
Tanimoto T; Nakatsu R; Fuke I; Ishikawa T; Ishibashi M; Yamanishi K; Takahashi M; Tamura S
Vaccine; 2005 Aug; 23(37):4598-609. PubMed ID: 15964668
[TBL] [Abstract][Full Text] [Related]
2. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Johansson BE; Kilbourne ED
Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
[TBL] [Abstract][Full Text] [Related]
3. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
[TBL] [Abstract][Full Text] [Related]
4. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
5. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
6. Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada.
Abed Y; Hardy I; Li Y; Boivin G
J Med Virol; 2002 Aug; 67(4):589-95. PubMed ID: 12116009
[TBL] [Abstract][Full Text] [Related]
7. Influenza A viruses possessing type B hemagglutinin and neuraminidase: potential as vaccine components.
Horimoto T; Iwatsuki-Horimoto K; Hatta M; Kawaoka Y
Microbes Infect; 2004 May; 6(6):579-83. PubMed ID: 15158192
[TBL] [Abstract][Full Text] [Related]
8. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
Kilbourne ED; Cerini CP; Khan MW; Mitchell JW; Ogra PL
J Immunol; 1987 May; 138(9):3010-3. PubMed ID: 3571981
[TBL] [Abstract][Full Text] [Related]
9. Stability of neuraminidase in inactivated influenza vaccines.
Sultana I; Yang K; Getie-Kebtie M; Couzens L; Markoff L; Alterman M; Eichelberger MC
Vaccine; 2014 Apr; 32(19):2225-30. PubMed ID: 24613525
[TBL] [Abstract][Full Text] [Related]
10. Difficulties in standardizing the neuraminidase content of influenza vaccines.
Gérentes L; Kessler N; Aymard M
Dev Biol Stand; 1999; 98():189-96; discussion 197. PubMed ID: 10494973
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
[TBL] [Abstract][Full Text] [Related]
12. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
13. Neuraminidase assays.
Aymard M; Ferraris O; Gerentes L; Jolly J; Kessler N
Dev Biol (Basel); 2003; 115():75-83. PubMed ID: 15088778
[TBL] [Abstract][Full Text] [Related]
14. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience.
Johansson BE; Moran TM; Bona CA; Popple SW; Kilbourne ED
J Immunol; 1987 Sep; 139(6):2010-4. PubMed ID: 3624874
[TBL] [Abstract][Full Text] [Related]
15. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice.
Qiu M; Fang F; Chen Y; Wang H; Chen Q; Chang H; Wang F; Wang H; Zhang R; Chen Z
Biochem Biophys Res Commun; 2006 May; 343(4):1124-31. PubMed ID: 16580631
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE.
Creskey MC; Li C; Wang J; Girard M; Lorbetskie B; Gravel C; Farnsworth A; Li X; Smith DG; Cyr TD
Vaccine; 2012 Jul; 30(32):4762-70. PubMed ID: 22643214
[TBL] [Abstract][Full Text] [Related]
17. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
19. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
Pushko P; Tumpey TM; Bu F; Knell J; Robinson R; Smith G
Vaccine; 2005 Dec; 23(50):5751-9. PubMed ID: 16143432
[TBL] [Abstract][Full Text] [Related]
20. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Johansson BE; Pokorny BA; Tiso VA
Vaccine; 2002 Feb; 20(11-12):1670-4. PubMed ID: 11858877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
